S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

$37.14
-1.85 (-4.74%)
(As of 04/12/2024 ET)
Today's Range
$36.84
$39.49
50-Day Range
$37.14
$52.35
52-Week Range
$2.82
$53.82
Volume
257,798 shs
Average Volume
301,797 shs
Market Capitalization
$1.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.60

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.7% Upside
$55.60 Price Target
Short Interest
Bearish
14.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.65mentions of Soleno Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.23 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.23) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

163rd out of 921 stocks

Electromedical Equipment Industry

3rd out of 17 stocks

SLNO stock logo

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

SLNO Stock News Headlines

Soleno Therapeutics (NASDAQ:SLNO) Shares Down 3.2%
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Soleno Therapeutics (NASDAQ:SLNO) Stock Price Down 3.2%
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
SLNO Apr 2024 40.000 put
SLNO Apr 2024 35.000 put
Soleno Therapeutics Inc.
SLNO Apr 2024 65.000 call
SLNO Mar 2024 40.000 call
SLNO Mar 2024 22.500 put
SLNO Mar 2024 60.000 call
SLNO Mar 2024 45.000 put
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/12/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:SLNO
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$55.60
High Stock Price Target
$93.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+49.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-38,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.16 per share

Miscellaneous

Free Float
24,768,000
Market Cap
$1.21 billion
Optionable
Optionable
Beta
-1.56
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 54)
    President, CEO, COO & Director
    Comp: $835.2k
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 60)
    Chief Financial Officer
    Comp: $539k
  • Ms. Patricia C. Hirano (Age 58)
    Vice President of Regulatory Affairs
    Comp: $423.8k
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., Senior Vice President of Drug Development
  • Ms. Meredith Manning M.B.A. (Age 51)
    Chief Commercial Officer
  • Ms. Kristen Yen M.S. (Age 55)
    Vice President of Clinical Operations
    Comp: $317.19k

SLNO Stock Analysis - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price target for 2024?

5 equities research analysts have issued 12 month price objectives for Soleno Therapeutics' stock. Their SLNO share price targets range from $35.00 to $93.00. On average, they expect the company's stock price to reach $55.60 in the next twelve months. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2024?

Soleno Therapeutics' stock was trading at $40.25 at the start of the year. Since then, SLNO stock has decreased by 7.7% and is now trading at $37.14.
View the best growth stocks for 2024 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02.

When did Soleno Therapeutics' stock split?

Soleno Therapeutics shares reverse split before market open on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLNO) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners